Razoxane
Suppliers
Names
[ CAS No. ]:
21416-67-1
[ Name ]:
Razoxane
[Synonym ]:
4,4'-propylenebis(piperazine-2,6-dione)
4,4'-Propane-1,2-diyldipiperazine-2,6-dione
4,4'-(1-Methylethylene)bis(2,6-piperazinedione)
dl-1,2-bis(3,5-dioxopiperazin-1-yl)-propane
Propyliminum
RAZOXANUM
1,2-bis(3,5-dioxopiperazin-1-yl)-propane
(+)-1,2-bis(3,5-dioxopiperazinyl)propane
(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane
Razoxane
Chemical & Physical Properties
[ Density]:
1.333g/cm3
[ Boiling Point ]:
531.5ºC at 760mmHg
[ Melting Point ]:
193ºC
[ Molecular Formula ]:
C11H16N4O4
[ Molecular Weight ]:
268.26900
[ Flash Point ]:
275.3ºC
[ Exact Mass ]:
268.11700
[ PSA ]:
98.82000
[ Vapour Pressure ]:
1.33E-13mmHg at 25°C
[ Index of Refraction ]:
1.534
[ Storage condition ]:
room temp
[ Water Solubility ]:
DMSO: soluble40mg/mL
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- TL6389900
- CHEMICAL NAME :
- 2,6-Piperazinedione, 4,4'-propylenedi-
- CAS REGISTRY NUMBER :
- 21416-67-1
- BEILSTEIN REFERENCE NO. :
- 0821182
- LAST UPDATED :
- 199612
- DATA ITEMS CITED :
- 15
- MOLECULAR FORMULA :
- C11-H16-N4-O4
- MOLECULAR WEIGHT :
- 268.31
- WISWESSER LINE NOTATION :
- T6VMV ENTJ EY1&1- ET6VMV ENTJ
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 3650 mg/kg/2Y-I
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - hematuria Blood - aplastic anemia
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 600 mg/kg/34W-I
- TOXIC EFFECTS :
- Blood - leukopenia
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 6467 mg/kg/6Y-I
- TOXIC EFFECTS :
- Blood - normocytic anemia Blood - thrombocytopenia
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 500 mg/kg
- TOXIC EFFECTS :
- Tumorigenic - active as anti-cancer agent
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 693 mg/kg/77W-I
- TOXIC EFFECTS :
- Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
- TYPE OF TEST :
- TD - Toxic dose (other than lowest)
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 4650 mg/kg/2Y-C
- TOXIC EFFECTS :
- Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
- TYPE OF TEST :
- TD - Toxic dose (other than lowest)
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 2693 mg/kg/3Y-C
- TOXIC EFFECTS :
- Tumorigenic - Carcinogenic by RTECS criteria Skin and Appendages - tumors
- TYPE OF TEST :
- TD - Toxic dose (other than lowest)
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 3650 mg/kg/2Y-I
- TOXIC EFFECTS :
- Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
- TYPE OF TEST :
- Micronucleus test
MUTATION DATA
- TEST SYSTEM :
- Rodent - hamster
- DOSE/DURATION :
- 100 mg/kg
- REFERENCE :
- BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 52,725,1985
Safety Information
[ RIDADR ]:
NONH for all modes of transport
[ RTECS ]:
TL6389900
Articles
J. Med. Chem. 51 , 6740-51, (2008)
The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared ...
Toxicol. Mech. Methods 18 , 217-27, (2008)
ABSTRACT Drug-induced phospholipidosis (PL) is a condition characterized by the accumulation of phospholipids and drug in lysosomes, and is found in a variety of tissue types. PL is frequently manifes...
J. Clin. Oncol. 30(10) , 1042-9, (2012)
Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identify...